Course Outline & Learning Outcomes

Bioethics: An Open Educational Resource

Author

Brendan Shea, PhD

Published

August 3, 2026

0.1 Course Structure

This course consists of 12 lectures, each delivered in two parts (designed for a twice-weekly schedule). Online students watch both parts as a single unit. Alongside the lectures, students read and discuss 12 case study documents drawn from historical and contemporary bioethics.

The course is organized around the four principles of biomedical ethics — autonomy, beneficence, non-maleficence, and justice. Major ethical theories (utilitarianism, Kantian ethics, virtue ethics, care ethics, principlism) are introduced as lenses that ground and sometimes conflict over these principles.

0.2 Course-Level Learning Outcomes

By the end of the course, students will be able to:

  1. Identify and apply the four principles of biomedical ethics (autonomy, beneficence, non-maleficence, justice) to clinical and research scenarios.
  2. Analyze moral arguments — identifying premises, conclusions, hidden assumptions, and common fallacies.
  3. Compare how major ethical frameworks (utilitarian, Kantian, virtue, care, principlist) approach the same dilemma and yield different conclusions.
  4. Evaluate real and contemporary bioethics cases using appropriate legal, historical, and empirical context.
  5. Articulate their own reasoned position on a contested bioethical issue, engaging fairly with opposing views.

0.3 Lecture Topics at a Glance

# Lecture Part A Part B
1 Principles, Theories & Moral Reasoning Four principles; moral arguments Theories as lenses on the principles
2 History & the Clinical Relationship Hippocratic → Nuremberg → Belmont Autonomy, consent, truth-telling, confidentiality
3 Research Ethics RCT primer; historical abuses Vulnerability, equipoise, commercial funding, the replication crisis
4 Abortion Moral status arguments The Law and Reproductive Rights (US and global)
5 Autonomy, Paternalism & Reproduction Paternalism and its limits Making family: markets, surrogacy, parental rights
6 Genomics & Enhancement Reading genomes: prediction, privacy, dual use Engineering persons: CRISPR, enhancement, identity
7 End of Life Brain death, advance directives Euthanasia, MAID, disability critiques
8 Justice & Health Care Allocation Theories of justice; right to care Disparities, implicit bias, rationing
9 Public Health Ethics Vaccination, liberty vs. welfare Pandemic triage; COVID lessons
10 AI in Medicine How medical AI works and fails The fifth principle: explicability, consent, liability
11 Gender, Identity & Disability Gender-affirming care: deciding under uncertainty Disability ethics; mere vs. bad difference
12 Animal Ethics Moral status; animal research Factory farming; xenotransplantation

0.4 Lecture-Level Learning Outcomes

0.4.1 L1. Principles, Theories & Moral Reasoning

  • Define the four principles of biomedical ethics and give a clinical example of each.
  • Distinguish ethical claims from legal, religious, or personal-preference claims.
  • Identify the premises and conclusion of a moral argument written in ordinary prose.
  • Recognize common fallacies in bioethical reasoning (ad hominem, appeal to nature, slippery slope, naturalistic fallacy).
  • Summarize the core commitments of utilitarianism, Kantian ethics, virtue ethics, and care ethics.
  • Explain how each theory grounds or prioritizes the four principles differently.

1 Bioethics: Detailed Table of Contents

Target audience: high school / early college students. Each chapter is split into two parts (a/b) so it fits a typical week of class (two ~75 min sessions, or three 50 min sessions).

1.1 L2. History & the Clinical Relationship

1.1.1 L2a. From Hippocrates to the Belmont Report: A History

  • The Hippocratic tradition: “first, do no harm,” confidentiality, and what the original oath actually said (vs. what people think it said).
  • Pre-WWII medical ethics: paternalism as the default, eugenics movements in the US and Europe.
  • Nazi medical experiments and the Nuremberg Trials (1945–47).
  • The Nuremberg Code (1947): voluntary consent as the first principle.
  • Tuskegee Syphilis Study (1932–72): what happened, why it took 40 years to stop, and the public response.
  • The Belmont Report (1979) and the rise of bioethics as a discipline.
  • Why “ethics committees” and IRBs exist today.

Visual elements: - Image (public domain): Hippocrates bust, Wellcome Collection / Wikimedia Commons. - Image (public domain): Nuremberg Doctors’ Trial photograph (US National Archives). - Image (public domain): Tuskegee study photo from CDC archives (the well-known photo of a doctor drawing blood from a subject). - Figure (code-generated): timeline of bioethics milestones, 1900–2000, with key events as labeled markers. - Table: Side-by-side comparison of Nuremberg Code (1947), Declaration of Helsinki (1964), and Belmont Report (1979) — date, audience, key principles. - Sidebar: “Where does the word ‘bioethics’ come from?” (Van Rensselaer Potter, 1970).

1.2 L3. Research Ethics

1.2.1 L3a. How Clinical Research Works (and Why It’s Different from Care)

  • What a randomized controlled trial is: randomization, blinding (single, double), placebo, control group, intention-to-treat analysis.
  • Phases of clinical trials (I → IV) in plain language.
  • The crucial distinction: research aims to produce generalizable knowledge; clinical care aims to benefit this patient. The same person doing both creates tension.
  • The therapeutic misconception: when participants believe an experimental treatment is being chosen for their benefit.
  • Why volunteers in early-phase trials face risk with little personal upside.

Visual elements: - Figure (code-generated): diagram of a parallel-group RCT — participants enrolled, randomized, two arms (treatment / placebo), followed to outcome. - Figure (code-generated): funnel showing trial phases I–IV with typical sample sizes and goals at each phase. - Table: Research vs. clinical care — goals, who benefits, who pays, what governs it (IRB vs. medical license). - Sidebar: “What does ‘double-blind’ actually mean?” with a small example.

1.2.2 L3b. Vulnerability, Equipoise, Money, and Trustworthy Knowledge

The systematic ethics of clinical trials, organized around one spine — vulnerability as power and pressure, not personality.

  • The three founding scandals (Nazi experiments, Willowbrook, Tuskegee) and the consent / harm / justice failures each forced into oversight.
  • A working taxonomy of vulnerability (cognitive, juridic, deferential, medical, allocational, infrastructural) — used as the analytic lens for the rest of the lecture; the two-sided justice point (wrongful exploitation and wrongful exclusion; FDORA diversity law).
  • The three Belmont principles as concrete IRB review questions; the “You Are the IRB” protocol simulation.
  • Clinical equipoise as the moral clock: it both licenses a trial (genuine community uncertainty) and ends it (early stopping for harm, benefit, or futility); why trials stopped early for benefit overestimate effects; placebo disputes reframed as equipoise disputes.
  • Placebo, poverty, and global research: the short-course AZT trials (Lurie & Wolfe vs. Varmus & Satcher) as allocational/infrastructural vulnerability; post-trial access.
  • Research without a trial: Henrietta Lacks, broad consent, the rewritten Common Rule, and DNA re-identification.
  • Commercial funding and conflict of interest: the Dan Markingson case (University of Minnesota, 2003–04) as a worst-case convergence of every vulnerability type; why disclosure is a floor and structural firewalls are the fix.
  • The replication crisis as a subject-protection problem: why most findings can be false (Ioannidis), p-hacking and HARKing in plain language, systemic evidence (psychology ≈39%; preclinical cancer 6/53), the Aβ*56 Alzheimer’s and Surgisphere cases, and how AI worsens the threat (synthetic data, paper mills, faster p-hacking).
  • Research misconduct (fabrication, falsification, plagiarism) and the structural fixes: preregistration, registered reports, data sharing, replication.

Visual elements: - Table: Kipnis-style taxonomy of vulnerability — type, the pressure, a clinical example. - Figure (code-generated): mapping of Belmont principles → IRB protections (three-column diagram). - Table: equipoise “clock runs out” — harm / benefit / futility stopping triggers. - Figure (code-generated): placebo decision tree, framed as nested equipoise questions. - Case box: the AZT debate (Lurie & Wolfe vs. Varmus & Satcher); the Markingson case context box and the 2015 Minnesota Legislative Auditor findings. - Table: weak vs. strong COI safeguards (disclosure vs. structural firewall). - Worked example: how testing 20 subgroups manufactures a false positive (p-hacking / HARKing). - Discussion prompts: IRB vaccine-in-prisons; trusted specialist paid per enrollee; a manipulated landmark trial (paying off the Part A opioid-letter thread).

1.3 L4. Abortion

1.3.1 L4a. Moral Status and the Major Philosophical Arguments

  • A short biology primer: zygote → embryo → fetus → viability → term.
  • Four candidate criteria for moral status: biological humanity, personhood, sentience, viability — what each implies.
  • Thomson’s violinist argument (1971): bodily autonomy even granting fetal personhood.
  • Marquis’s future-like-ours argument (1989): why killing a fetus is wrong for the same reason killing an adult is.
  • Hurthouse (1991) on virtue theory and abortion, and on what traditional accounts miss

Visual elements: - Figure (code-generated): timeline of fetal development with markers at key developmental milestones (heartbeat detectable, neural development, viability) — neutrally labeled. - Figure (code-generated): concept map of the four moral status criteria and which views each supports. - Table: Thomson’s violinist vs. Marquis’s future-like-ours — what each argues, what it concedes, common objections. - Discussion prompt: “Is the violinist analogy a fair comparison? Where does it break down?”

1.3.2 L4b. The Law and Reproductive Rights

  • The Deep History of Reproductive Law: Ancient Roman and Greek exposure and infanticide practices; English Common Law’s “quickening” standard (16–20 weeks); early American midwife-controlled healthcare; the late-19th-century AMA professionalization and criminalization campaign.
  • Legal Literacy Primer: Statutory vs. Common Law; how case precedents develop; the principle of stare decisis and the moral weight of reliance interests; the high bar and criteria for overturning judicial precedents.
  • The U.S. Constitutional Arc: Roe v. Wade (1973) and the trimester privacy framework; Planned Parenthood v. Casey (1992) and the viability/undue burden standard; Dobbs v. Jackson (2022) and the history/democratic federalism model.
  • The Bedside-Law Collision: Post-Dobbs state-by-state 2x2 patchwork (total bans, limits, trigger laws, shield laws); the “chilling effect” under severe criminal threats; clinical exceptions ambiguity in ectopic pregnancies and previable preeclampsia; clinician moral distress and OB-GYN deserts.
  • Global Perspectives & Coercive Anti-Natalism: The European compromises (early gestational limits with universal funding/counseling); Canada’s decriminalized medical model; China’s One-Child Policy (1979–2015) forced sterilizations/abortions and its sudden demographic Three-Child pivot.
  • Coercive Pro-Natalism & Paternalism: Demographic collapse and falling fertility rates; Singapore’s supportive pro-natal incentives; Romania’s Decree 770 (1966) total bans, gynecological monthly audits, and the resulting illegal abortion and orphanage crises.
  • Conceptual Integration: The Four Principles Grid comparing pro-choice and pro-life interpretations of Autonomy, Beneficence, Non-Maleficence, and Justice; the logical coherence of gradualist/moderate moral frameworks.

Visual elements: - Image (premium generated asset): “The Sovereign’s Cradle” (wooden cradle wrapped in legal ribbons and a state seal) on the opening thought experiment. - Table: Side-by-side comparative grid of Roe vs. Casey vs. Dobbs (constitutional basis, legal threshold, and regulatory power). - Table: The Four Principles Grid comparing liberal and conservative interpretations of Autonomy, Beneficence, Non-Maleficence, and Justice across reproductive choices. - 2x2 Grid: The post-Dobbs U.S. legal patchwork matrix.

1.4 L5. Autonomy, Paternalism, and Reproduction

1.4.1 L5a. Paternalism and Its Limits

The lecture builds one tool — Mill’s framework for justified paternalism — and stress-tests it on the two hardest places medicine uses it: drug policy and pregnancy.

  • The Millian framework. Paternalism defined (interference, without consent, only because it is for the person’s good); Mill’s harm principle and his own exceptions (children, the bridge); soft vs. hard paternalism distinguished by whether the overridden choice is compromised or competent; the three-question test (competent? voluntary? harm to the chooser alone?).
  • Hard paternalism, defended. Prescription-only opioids as a piece of hard paternalism we accept, and the actual justification for it (addiction, information asymmetry, irreversibility, the choosing-self/later-self gap) — which works by treating the choice as less voluntary than it appears.
  • Why drug policy is hard. Unrestricted 19th-century opiates (patent medicines, infant “soothing syrups”) as the case for control; Prohibition (1920–33) as the case against bans; a cross-national comparison (US, Portugal, Netherlands, Singapore, Japan) showing stringency does not predict outcomes; two coherent models (consistent strictness vs. funded decriminalization) and the soft-paternalism middle (tobacco taxes, the 21 drinking age, naloxone).
  • Pregnancy as a paternalism problem. The second-party complication for Mill’s third question; a spectrum of interventions from soft (risk messaging) to hard (criminal prosecution), read as a ladder; Ferguson v. City of Charleston (2001) as the hard end’s mechanism; Tennessee’s expired fetal-assault law and Faherty et al. (2019) as the result (deterrence-of-care); Brittney Poolaw (Oklahoma, 2021) and the Paltrow–Flavin count; ACOG Opinions 473/664 as the professional line.
  • Partial autonomy — the hardest case. Where autonomy is real but incomplete: the addicted chooser, the pregnant patient, and the adolescent; mature-minor doctrine and confidential adolescent care.

Visual elements:

  • Figure (code-generated): a Mill-style decision tree for paternalistic intervention — competent? voluntary? harming only self? — applied to one drug-policy case and one pregnancy case.
  • Table: cross-national drug policy — overdose and incarceration rates against policy stance, showing stringency does not track outcomes.
  • Table: the spectrum of interventions aimed at pregnant women, soft to hard, with the paternalism type of each.
  • Scoreboard table: worked cases (sedated patient, age limits, cigarette taxes, prescription opioids, prenatal-drug prosecution) sorted soft/hard with the verdict on each.
  • Sidebar: “Why does ACOG oppose criminalizing substance use in pregnancy?” — the convergence of the ethical argument and the population data.
  • Discussion prompt: “If alcohol use during pregnancy can harm a future person, why don’t we prosecute it the way we prosecute meth use? What does your answer commit you to about every legal substance?”

1.4.2 L5b. Making Family: Markets, Surrogacy, and Parental Rights

The technology is explained in service of the ethics: enough IVF/PGT/surrogacy to argue about, not a stand-alone tour.

  • A short technological primer: IVF, ICSI, PGT, and the distinction between gestational and traditional surrogacy.
  • The commodification debate: Elizabeth Anderson’s critique that markets in gametes and gestation wrong both the providers and the resulting children; John Robertson’s procreative liberty defense; Michael Sandel’s broader What Money Can’t Buy frame.
  • Commercial vs. altruistic surrogacy regimes: California’s accommodating contract law; New York’s 2021 Child-Parent Security Act; India’s 2015 commercial-surrogacy ban; Thailand’s 2015 ban; Mexico’s reopening; the UK’s altruistic-only model.
  • Parental rights: In re Baby M (NJ, 1988, traditional surrogacy and the limits of contract) and Johnson v. Calvert (CA, 1993, gestational surrogacy and the intent test).
  • Gamete markets: sperm and egg donation, anonymous vs. open-identity regimes, the “$50,000 Ivy League egg” price tier, recent moves toward donor-anonymity bans.
  • Frozen embryos and the LePage aftershock: LePage v. Mobile Infirmary Clinic (Alabama, Feb 2024) ruling that frozen embryos are “extrauterine children” under the wrongful-death statute; the IVF clinic shutdowns that followed; the Alabama legislative fix; what it suggests about institutional fragility post-Dobbs. (Embryo moral status proper stays in L4 — the focus here is what the legal recognition of embryos does to reproductive practice.)
  • Brief mentions: posthumous reproduction; savior siblings (Nash family).

Visual elements:

  • Figure (code-generated): IVF + surrogacy flow with the points at which a parental-rights question can arise marked.
  • Table: commercial vs. altruistic surrogacy regimes across selected jurisdictions — what’s permitted, what compensation is allowed, who is the legal parent.
  • Table: Anderson vs. Robertson vs. Sandel on the commodification debate — what each accepts, what each rejects.
  • Case box: Baby M (1988) — traditional surrogacy, contract, and the parental-rights split.
  • Case box: LePage v. Mobile Infirmary (2024) — facts, IVF clinic responses, legislative fix.
  • Discussion prompt: “Is paying $50,000 for an egg from an Ivy League donor different from paying $5,000 for an egg from a typical donor? Why or why not?”

1.5 L6. Genomics & Enhancement

1.5.1 L6a. Reading Genomes: Prediction, Privacy, and Dual Use

The lecture is organized around one concept — geneticization (Abby Lippman, 1991): the recurring tendency to read human differences, risks, and identities as primarily genetic. Each section below is an instance of that pull, and the places it goes wrong.

  • The Human Genome Project as the lecture’s hinge: map-first/sequence-later (1990–98); the public-vs-Celera race (1998–2003) and Craig Venter’s whole-genome shotgun approach; the “working draft” announced at the June 2000 White House press conference; completion in 2003. The crucial framing point: HGP proponents (Francis Collins 1999) promised that by 2010, cheek-swab risk prediction and pharmacogenomic prescribing would be routine, and common diseases like diabetes and schizophrenia would be tractable. What actually arrived was harder — GWAS produced thousands of small-effect variants, “missing heritability,” and only modest clinical payoff. The gap between promise and delivery is the lecture’s frame.
  • Geneticization, genetic reductionism, and genetic determinism: the named concept (Lippman 1991) and why every later section is an instance of the same pull. Brief contrast with gene-by-environment interaction as the working scientific picture.
  • A minimal vocabulary primer: gene, allele, genome, mutation, germline vs. somatic — enough to read a genetic-test report, no inheritance-pattern tour.
  • Whose genome is “the” genome? The HGP and Celera reference sequences are composites: roughly 74% of the HGP reference is from a single anonymous male donor (the “Buffalo man”); roughly 71% of the Celera sequence is from Venter himself. This sets up the ancestry-bias problem — GWAS and polygenic risk scores are overwhelmingly trained on European-ancestry data, and perform worse for everyone else. Recent moves toward a human pangenome reference are the corrective.
  • Prenatal screening: NIPT (non-invasive prenatal testing) and the >90% Down syndrome termination rate; brief Adrienne Asch reference (full disability-rights treatment held for L11).
  • Carrier and predictive testing: the Ashkenazi screening model as a community-led success; BRCA testing in adults; the harder question of testing healthy children for adult-onset conditions (Huntington’s, BRCA) — Feinberg’s “open future” applied to information. Live debate: newborn genomic sequencing (BabySeq, NYC GUARDIAN) and the ACMG-AAP split over which conditions to return.
  • Direct-to-consumer testing: 23andMe and ancestry services; the 2023 23andMe data breach and what it exposed about genetic-data security; the implications of one relative’s test for everyone who shares their genome.
  • Race, genetics, and population descriptors. Not the primary topic, but a thread the technology forces onto the table. Two sides need separating: (1) DTC ancestry essentialism — “you are 23% Italian” promises a genetic precision the science doesn’t deliver, and the underlying reference panels are themselves social-political artifacts; (2) Race in genetic research — the 2023 National Academies report (Using Population Descriptors in Genetics and Genomics Research) is the current professional-body consensus. Its core recommendation: race should not be used as a proxy for genetic variation, because race is sociopolitically constructed, and population descriptors should be selected deliberately, tailored to the study question, with environmental factors directly measured rather than imputed from race. A useful short example: the term “Caucasian” originated with Blumenbach’s eighteenth-century ranking of skulls and carries no scientific content.
  • Forensic genealogy: GEDmatch and the Golden State Killer (2018) — how a recreational-genealogy database became a criminal-investigation tool; the consent question for the millions of people whose distant relatives uploaded data. Live debate: Maryland (2021) and Montana (2021) became the first U.S. states to regulate investigative genetic genealogy by statute; the DOJ’s 2019 interim policy governs federal use.
  • The legal floor: GINA (2008) — what it covers (health insurance, employment) and what it does not (life, disability, long-term-care insurance, the military). Live debate: state-level fixes for the GINA gap, including Florida’s 2020 law restricting life insurers’ use of genetic test results.
  • Dual-use genomics and biosecurity: mail-order DNA synthesis and the 2023 White House framework for nucleic-acid synthesis screening; gain-of-function research as the closest analogue (callback to L3 misconduct + the dual-use literature). This is where students meet biosecurity as a distinct research-ethics frame.
  • Sidebar — Where modern genomic bioethics came from: the ELSI program (Ethical, Legal, and Social Implications), mandated as 3–5% of HGP funding from 1990 onward; the first institutional bioethics program tied to a single science, and a parallel to the Belmont arc in L2.

Visual elements:

  • Figure (code-generated): timeline of the HGP and its aftermath — 1990 launch → 1998 Celera enters → 2000 “working draft” → 2003 completion → 2010 (Collins’ predicted “individualized medicine”) with what actually arrived noted.
  • Figure (code-generated): an annotated mock 23andMe-style report — what it actually shows (and doesn’t) about ancestry and disease risk.
  • Table: What GINA covers vs. what it doesn’t — broken out by insurance line, employment, and federal vs. state law.
  • Table: The NASEM 2023 framework in plain English — race, ethnicity, geography, genetic ancestry, genetic similarity: what each captures, what each doesn’t, when to use each. (Adapted from Table S-1 of the report.)
  • Case box: The Golden State Killer and GEDmatch — facts, the investigative method, and the consent question for non-uploaders.
  • Case box: The Buffalo-man / Venter reference-genome story — vivid, short, and concrete entry into the representativeness problem.
  • Sidebar: “Why does mail-order DNA synthesis worry biosecurity experts?” — synthetic biology dual-use primer.
  • Sidebar: “What did the HGP actually deliver vs. what was promised?” — Collins 1999 predictions side by side with a 2026 reality check.
  • Discussion prompt: “Should parents be able to test a healthy 8-year-old for an adult-onset BRCA mutation? Does your answer change if the condition is Huntington’s instead?”
  • Discussion prompt: “A study reports that a particular variant is more common in ‘African American’ participants. The NASEM 2023 report says race shouldn’t be used as a proxy for genetic variation. What should the study have done instead, and what should a clinician do with this finding today?”

1.5.2 L6b. Engineering Persons: CRISPR, Enhancement, and Identity

The lecture’s spine is the treatment-vs-enhancement distinction — normatively load-bearing but conceptually unstable — and every case in the lecture re-runs the same argument against it.

  • The treatment-enhancement distinction and why it keeps collapsing. Three competing accounts: the professional-domain account (whatever medicine declines to do — collapses under medicalization); the normal-function account (Boorse/Daniels — what restores species-typical function; collapses on prevention and on disability cases); the disease-based account (Gert/Culver/Clouser — treatment addresses a diagnosable malady; collapses under nosological elasticity, as new “diseases” get coined). The point is not that one account wins. The point is that the distinction does real ethical work and keeps unraveling under scrutiny — which is why every downstream case in the lecture is contested in the same way.
  • Somatic vs. germline editing — the distinction that does most of the moral work in the second half.
  • CRISPR-Cas9 in plain language: a programmable “find-and-replace” for DNA.
  • Approved somatic therapies: Casgevy (sickle-cell disease, FDA 2023), Luxturna (retinal dystrophy). The somatic case is largely settled; the germline case is not.
  • The He Jiankui case (2018), briefly. The CCR5 edit in twin embryos, international condemnation, the 2019 prison sentence and 2022 release, and what consensus has and has not formed since. Held short here because the He Jiankui paired case study carries the full narrative.
  • Cognitive enhancement in healthy adults. Off-label use of prescription stimulants — Adderall, modafinil — by college students and shift workers (~17% of US college students report nonmedical stimulant use; rates rise sharply in nursing and medical training). This is the most common form of enhancement actually happening today, and it sits exactly on the treatment-vs-enhancement collapse: Adderall for diagnosed ADHD vs. Adderall for a healthy student studying for boards. ADHD diagnosis criteria have expanded alongside the demand for the drugs — Section 2.3 of the SEP article in concrete form.
  • The non-identity problem (Parfit) in concrete form: can you wrong someone by choosing the conditions of their existence? Parfit’s “14-year-old girl” thought experiment.
  • The enhancement debate (three positions, not four):
    • Savulescu: procreative beneficence — parents have reason to select the best possible child.
    • Sandel: enhancement reflects a “drive to mastery” that corrodes appreciation of life as gift. Worth a verbatim quote-card from The Case Against Perfection.
    • Habermas: the “ethical self-understanding of the species” and the asymmetry between making a person and growing one — the child has not consented to be the project of someone else’s life plan.
  • Feinberg’s “right to an open future” applied to enhancement — the original home of the argument, in contrast with its L6a use for information.
  • Live edge: polygenic embryo selection. US fertility-clinic startups (Orchid Health, Heliospect) now offer trait selection on the basis of polygenic risk scores, including for predicted IQ. Sits at the intersection of embryo selection and enhancement. Currently legal in the US and unregulated.

Visual elements:

  • Figure (code-generated): CRISPR-Cas9 mechanism — guide RNA, Cas9, target sequence, cut — at the lowest fidelity that still works.
  • Table: Three accounts of the treatment-enhancement line — professional-domain / normal-function / disease-based — and where each one collapses.
  • Table: Casgevy (somatic, settled) vs. He Jiankui (germline, condemned) — what differs, what carries the moral weight.
  • Table: Savulescu vs. Sandel vs. Habermas on enhancement — what each accepts, rejects, and why.
  • Case box: The non-identity problem in concrete form — Parfit’s “14-year-old girl” thought experiment.
  • Case box: Polygenic embryo selection for IQ — Orchid Health and Heliospect as the operating business model, currently legal in the US.
  • Discussion prompt: “Your roommate, a healthy nursing student, asks you to share your Adderall the night before NCLEX. Apply the three treatment-enhancement accounts to her request. Which one makes the strongest case for ‘no’?”
  • Discussion prompt: “If parents could safely give their child a 10-point IQ boost, should they? Does your answer change if the technique is only available to families who can pay $50,000?”

1.6 L7. End of Life

1.6.1 L7a. Death, Dying, and Advance Planning

Spine: the lecture follows Nancy Cruzan as a recurring case, organized around one framing question — “When is a person gone, and once we’re not sure, who decides what happens next?” The clinical material answers the first half; the legal/ethical material answers the second.

  • Defining the end of life clinically: brain death, coma, persistent vegetative state, minimally conscious state, locked-in syndrome — what’s different about each (arousal vs. awareness).
  • The 1968 Harvard criteria, the move to whole-brain death, and how the Uniform Determination of Death Act (1981) codified it.
  • Current debates on defining / operationalizing death (whole-brain vs. higher-brain vs. circulatory — light touch).
  • Advance directives in everyday terms:
    • Living wills
    • Durable power of attorney for health care
    • POLST / MOLST forms (and why these are different from a living will)
  • Surrogate decision-making standards:
    • Substituted judgment (“what would this patient have wanted?”)
    • Best interest (“what’s best for someone in this situation?”)
  • High-profile cases compared: Karen Ann Quinlan (1976, who decides / ventilator), Nancy Cruzan (1990, the “clear and convincing evidence” standard that drove the spread of directives), Terri Schiavo (1990–2005, the payoff case — the tools exist, but a divided family and a missing directive still tore everything apart).
  • Contemporary tie-in: Adriana Smith (Georgia, 2025) — being dead vs. being allowed to die, where brain-death, abortion, and advance-directive law collide.

Visual elements: - Figure (code-generated): spectrum diagram of consciousness states from coma to full awareness, with diagnostic criteria for each. - Figure (code-generated): flowchart, “Who decides?” — patient → designated proxy → next of kin hierarchy, with state variation note. - Table: Living will vs. durable power of attorney vs. POLST — what each is, who fills it out, when it kicks in. - Case box: The Schiavo case in brief — timeline, legal battles, what made it different from Quinlan and Cruzan. - Sidebar: A sample advance directive form (simplified, illustrative).

1.6.2 L7b. Euthanasia, Assisted Death, and Their Critics

Spine: anchored on Brittany Maynard (terminal glioblastoma, moved to Oregon, died 2014), structured as an argument map around one disputed line — the line between killing and letting die. The pro voices and the critics each get a fair hearing.

  • A vocabulary that students consistently confuse:
    • Active euthanasia (administering a lethal substance)
    • Passive euthanasia (withholding or withdrawing treatment)
    • Withdrawal of treatment (not the same as killing)
    • Physician-assisted death / MAID (prescribing, not administering)
  • The philosophical chain (challenge → reply → pro → critics):
    • Rachels (1975): the active/passive distinction carries no moral weight in itself (Smith & Jones).
    • Foot (1977): the distinction survives once re-grounded in negative vs. positive duties.
    • Brock (1992): the autonomy + well-being case for voluntary active euthanasia — the same values that justify refusing treatment.
    • Singer: the quality-of-life / anti-sanctity-of-life view — and why its edge invites the disability backlash.
    • Velleman (1992): the best secular objection — establishing a right to die can harm the vulnerable by removing the “no choice” default.
    • Harriet McBryde Johnson vs. Singer (“Unspeakable Conversations,” 2003): the disability-rights answer with a named voice.
  • The doctrine of double effect — and whether palliative sedation falls under it or is “slow euthanasia.”
  • Where MAID is legal (Oregon since 1997, Canada since 2016 via Carter, several others) and where it’s expanding; Oregon’s 25+ years of data.
  • Disability community critiques: “better dead than disabled” worries, coercion concerns, the “duty to die,” and access disparities.
  • The psychiatric MAID controversy — Belgium, Netherlands, and Canada’s repeated pause (now to 2027) on mental-illness-only eligibility.

Visual elements: - Figure (code-generated): concept map distinguishing active/passive, voluntary/non-voluntary/involuntary, killing/letting die. - Scoreboard table: Rachels vs. Foot — what each thinks does the moral work. - Table: MAID legal status across selected jurisdictions (US states, Canada, Netherlands, Belgium, Switzerland). - Case box: Rachels’ “Smith and Jones in the bathtub” thought experiment. - Discussion prompt: “Is there a moral difference between turning off a ventilator and giving a lethal injection? Why or why not?” - Case box: Noelia Castillo (Spain, 2026) — the psychiatric-MAID frontier; the paired case study. - Discussion debrief: logical vs. empirical slippery slopes, using Canada’s trajectory.

1.7 L8. Justice & Health Care Allocation

1.7.1 L8a. Theories of Justice and the Right to Health Care

Spine: anchored on allocating a single scarce organ as the running application, opened by the case that shows what allocation looks like without a theory of justice — the Seattle “God Committee” (1962), which rationed early dialysis by judging patients’ “social worth” (job, church attendance, marital status). The motivating question: if not by social worth, then by what principle?

  • A short tour of four families of theories, in plain language — each run through the same organ-allocation problem:
    • Utilitarian — maximize total well-being / life-years saved (the logic behind QALYs and survival-benefit scoring).
    • Rawlsian — what would we choose behind a “veil of ignorance”? Protect the worst-off.
    • Libertarian (Nozick) — no one is owed health care; the organ is the donor’s to give (hence directed donation and the kidney-market debate).
    • Capabilities (Sen, Nussbaum) — restore the functioning people need to live a human life.
  • Organ allocation as the worked application: how UNOS prioritizes — “sickest first” vs. “best outcome” vs. “first-come”; opt-in vs. opt-out / presumed consent (Spain’s world-leading donation rate); directed/conditional donation; the ethics of paid organ markets (Iran, the only legal one); ability-to-pay distortions (registering in multiple states).
  • Is there a moral right to health care? Positive vs. negative rights; Norman Daniels’ argument from fair equality of opportunity.
  • Where the US stands: a country that treats food, housing, and education as partial rights but health care as mostly a market good. (Bridge to 8b via the expensive-cancer-drug coverage question.)

Visual elements: - Figure (code-generated): 2×2 grid of theories of justice along axes of “individual liberty ↔︎ collective welfare” and “outcome-focused ↔︎ rights-focused.” - Table: Four theories applied to one scarce organ — what each says about who gets it, and why. - Sidebar: Rawls’ original position, illustrated as a thought experiment. - Case box: The Seattle “God Committee” and the birth of bioethics commissions. - Discussion prompt: “Behind the veil of ignorance, what health system would you design?”

1.7.2 L8b. Why US Health Care Costs So Much — and Delivers So Little

Spine: two devices carry the facts. (1) The driving paradox — the US spends roughly double peer nations (~$13,000+/person, ~17–18% of GDP) yet ranks near the bottom of rich countries on life expectancy and infant/maternal mortality: spend the most, get less. (2) Follow one person through the patchwork — born (Medicaid/CHIP) → employer insurance → job loss → ACA exchange → uninsured gap → Medicare at 65 → Medicaid for nursing-home care. One life touches every program. The descriptive material is framed by 8a’s justice theories and ends on the value conflicts behind current debates.

  • The fragmented system, explained: employer-sponsored insurance (≈half of Americans; the tax exclusion), Medicare, Medicaid, the VA (actual government-run care), ACA exchanges, the individual market, and out-of-pocket / the uninsured.
  • A little history since 1945: the WWII wage-freeze accident that tied insurance to jobs (1943/’54); Truman’s failed national plan; Medicare & Medicaid (1965); EMTALA (1986, must treat in the ER); Clinton’s 1994 failure; the ACA (2010) — what changed, and what stubbornly didn’t (still employer-core, still not universal).
  • Why so expensive? The evidence: “it’s the prices, not the utilization” (Anderson et al.) — Americans don’t use more care, each unit costs more — plus multi-payer administrative overhead, fee-for-service incentives, drug prices, hospital consolidation, and little price transparency.
  • Why poorer outcomes? Access gaps plus social/behavioral drivers the system doesn’t control (obesity, firearms, vehicle deaths, opioids, inequality — the IOM’s “Shorter Lives, Poorer Health”). Honest nuance: not all of it is a health-system failure. Population disparities (life expectancy by race, maternal mortality) live here. (Implicit bias in the clinical encounter relocated to L9.)
  • What we’re genuinely best at: quaternary/specialty care (Mayo, Cleveland Clinic, MD Anderson), top-tier cancer survival, biomedical innovation, no waits for the well-insured.
  • Where we struggle: pricing, access, administrative burden, rural hospital closures, nursing/staff shortages and burnout (foregrounded for the nursing audience), and the recent life-expectancy decline.
  • Compare the world: universal coverage has many designs — UK NHS (government-run), Canada (single public insurer, private delivery), Germany (multi-payer sickness funds), Switzerland (regulated private mandate — the ACA’s cousin). Leaves students ready for the Medicare-for-All / public-option / market-reform debate.

Visual elements: - Figure (code-generated): scatter/bar — per-capita health spending vs. life expectancy across OECD countries, with the US as the visible outlier. - Figure (code-generated): “who covers whom” — US population by coverage source (employer, Medicare, Medicaid, exchange, uninsured) as a stacked bar. - Figure (code-generated): timeline of US health-financing milestones, 1945–present. - Table: Four models of universal coverage (UK / Canada / Germany / Switzerland) — who pays, who delivers, how it compares to a US program. - Discussion prompt: “You can change one feature of the US system. Which, and which 8a value does your choice serve?”

1.8 L9. Public Health Ethics

1.8.1 L9a. From Patient to Population

The lecture’s question: when may a society override individual liberty for the sake of collective health — and how would we know it has gone too far?

  • How public health ethics differs from clinical ethics: the unit of concern shifts from the individual patient to the population.
  • The tension, anchored in Mill (callback, L5a). The harm principle is the liberty default — but contagion makes “harm to others” literal and collective, which is exactly where the principle gets interesting. Public health is the standing exception that has to justify itself.
  • The test for that justification: Childress et al.’s five benchmarks — effectiveness, proportionality, necessity, least infringement, public justification. Not a separate topic from the liberty tension; the rubric for adjudicating it.
  • A short history of public health: sanitation, vaccination, fluoridation, tobacco control — the wins, and the resistance.
  • Jacobson v. Massachusetts (1905) and the legal basis for vaccine mandates — and its dark mirror, Buck v. Bell (1927), which cited Jacobson to uphold compulsory sterilization (callback to L2 eugenics): the same “public health necessity” logic turned to the unforgivable. The benchmarks — necessity, least infringement — are what is supposed to stop that slide.
  • Forward link to 9b: 9a is what the state may legitimately compel; 9b is what it may do when it cannot — or should not — reach for force.

Visual elements: - Figure (code-generated): side-by-side comparison of clinical ethics vs. public health ethics — unit of concern, primary value, key tensions. - Figure (code-generated): line graph showing disease incidence before and after major public health interventions (e.g., measles before/after vaccine). - Image (public domain): John Snow’s cholera map (1854), Wikimedia Commons. - Table: Childress et al.’s five “justificatory conditions” with an example for each. - Sidebar: “What did Jacobson actually decide?” — a short legal note (it upheld a $5 fine, not forced vaccination), paired with the Buck v. Bell warning about how the same logic was abused.

1.8.2 L9b. False Beliefs and Public Health: The Ethics of Correction

The lecture’s question: if giving people the facts doesn’t fix false medical beliefs — and can entrench them — what may a clinician or a state permissibly do instead, without manipulating people or simply declaring dissent irrational? COVID-19 is the springboard, but the target is the general problem.

  • The naïve view: the “deficit model.” People believe falsehoods because they lack information; the cure is education. This is where most students — and most clinicians — start.
  • Why facts don’t fix it — Dan Kahan. Identity-protective (cultural) cognition: on politically charged science, more scientific literacy predicts more polarization, not less. Reasoning is defending the tribe, not tracking the truth — so “explain harder” demonstrably fails.
  • Why correction can backfire — C. Thi Nguyen. The epistemic bubble (merely omits opposing voices; pops on contact with them) vs. the echo chamber (actively discredits outside sources, so contact makes things worse). Handing an echo-chamber member the CDC page can confirm their priors.
  • So should we stop trusting experts? No — trust the process — Naomi Oreskes. Why Trust Science?: science’s authority rests on organized, social skepticism (peer critique, replication), not individual genius. Merchants of Doubt: doubt is deliberately manufactured by actors who exploit that very openness (tobacco → climate → vaccines). The task becomes distinguishing earned distrust from cultivated denial.
  • Callbacks (no new thinkers):
    • The replication crisis (L3, Ioannidis): students already know science gets things wrong — that is the objection Oreskes answers (the warrant is self-correction, not infallibility).
    • Tuskegee (L2/L3): sometimes distrust is earned — some “false beliefs” are rational inferences from a real betrayal. The clinical-encounter evidence on dismissed symptoms and undertreated pain (relocated from L8b) is the population-level mechanism: people learn distrust.
    • Mill’s harm principle and marketplace of ideas (L5a): Mill bet truth wins an open contest — do echo chambers break the bet? Nudging or regulating belief is soft paternalism aimed at the intellect; run L5’s three-question test on it.
    • Autonomy requires understanding (L2b, consent): is a misinformed refusal even an autonomous choice — and who gets to rule the understanding “corrupted”?
  • The two case sites: the clinician facing one misinformed patient vs. the policymaker facing a misinformed population — the same dilemma at different altitudes. The resolution to end on is trustworthy process, not belief-engineering.

Visual elements: - Figure (code-generated): Kahan’s result, illustrated — belief polarization widening as science literacy rises (two diverging lines by cultural group), against the deficit model’s predicted convergence. - Figure (code-generated): a 2×2 / side-by-side contrasting the epistemic bubble and the echo chamber on two features — does it omit other voices, or actively discredit them? — with the predicted effect of “more exposure” for each. - Table: a ladder of responses to false medical belief, from rational persuasion → framing/nudges → platform regulation → mandates, each tagged with the L5 paternalism type and the autonomy worry it raises. - Case box: manufactured doubt — the tobacco industry’s “doubt is our product” memo, and the reused playbook (Oreskes), as a template students can spot in a contemporary health claim. - Discussion prompt: “A parent refuses a childhood vaccine on a false belief. Name one response that respects their autonomy and one that manipulates — and say what makes the difference.”

1.9 L10. AI in Medicine

1.9.1 L10a. How Medical AI Works and Where It Goes Wrong

Spine: one question asked of every system in the lecture — “What was the model actually trained to do, and is that the same as what we’re using it for?” Every failure case below (proxy variables, distribution shift, hallucination) is a gap between the trained task and the clinical task.

  • A jargon-free supervised learning primer: training data, features, labels, prediction — and the crucial point that the model learns whatever pattern predicts the label, not what we wish it learned.
  • A short generative AI primer at the same altitude: LLMs are trained to produce plausible continuations, not verified truths — which is why hallucination isn’t a bug to patch but the flip side of how they work.
  • Three kinds of medical AI, each with its signature failure mode:
    • Diagnostic (image classification — radiology, dermatology, pathology) → fails by distribution shift (trained on one population, deployed on another).
    • Predictive (risk scores — sepsis, readmission, deterioration) → fails by proxy variables and alert burden.
    • Generative (LLMs — patient questions, ambient scribes, draft replies) → fails by hallucination and sycophancy (telling the user what they want to hear).
  • Sources of algorithmic bias: unrepresentative training data; proxy variables; deployment drift (model performs worse over time as the world changes).
  • The Optum care-management algorithm (Obermeyer et al. 2019), kept brief in lecture — cost as a proxy for need systematically underestimated Black patients’ illness; a justice failure invisible from inside the accuracy metrics. (Full narrative carried by the paired case study.)
  • The Epic Sepsis Model, in two acts: Act I — Wong et al. (2021): claimed performance collapses under independent validation (callback: L3’s replication crisis — external validation is AI’s replication). Act II — the rebuilt model (Wong et al. 2026) validates well on AUC yet generates low-precision, high-volume alerts: passing the metrics is not the same as helping the patient. Alert fatigue as an ethics problem.
  • The hype cycle (callback to L6a’s HGP promise-vs-delivery frame): Hinton’s 2016 “stop training radiologists” prediction vs. the assistive reality a decade later.

Visual elements: - Figure (code-generated): supervised ML training-and-deployment pipeline, with the three failure points marked (bad labels, unrepresentative data, drift). - Figure (code-generated): the Optum proxy problem — two patients, equal sickness, unequal historical cost. - Table: diagnostic vs. predictive vs. generative medical AI — example, what it’s trained to do, signature failure, how it’s evaluated. - Quote card: Hinton (2016) on radiologists, with the ten-years-later reality check. - Sidebar: “Why does a model trained on Stanford patients underperform at a rural hospital?” - Discussion prompt: “You ask a chatbot about a medication and it answers fluently and wrongly. Why do fluent and wrong go together?”

1.10 L11. Gender, Identity & Disability

1.10.1 L11a. Gender-Affirming Care: Deciding Under Uncertainty

Spine: one question carries the lecture — what should medicine, families, and the state each do when the evidence is genuinely low-certainty and the stakes are high in both directions? The crucial analytical move, taught early and applied throughout: low-certainty evidence does not automatically favor either side. Precaution arguments (“no irreversible treatment without strong evidence”) and access arguments (“no withholding possibly life-saving treatment without strong evidence of harm”) both claim the same evidence base. This makes 11a the capstone of the course’s epistemology thread (evidence quality and equipoise from research ethics; adolescent partial autonomy from paternalism; dueling authorities and trust-the-process from public health).

  • A vocabulary primer: sex, gender identity, gender dysphoria (DSM-5-TR) — defined neutrally and clinically.
  • What care actually involves, by age and reversibility: social transition → puberty blockers → hormones → (rarely, for minors) surgery; what’s offered, when, with what assessments. Adult care framed briefly as the less-contested baseline.
  • The evidence debate, mapped fairly. What the systematic reviews actually found (low/very-low certainty on key outcomes) and why that finding cuts both ways. WPATH SOC8 reframed as one contested authority among several, not “the standard, basics only.”
  • The philosophical chain (named bioethicists, challenge→reply→pro→critic, per course standard): Giordano (the foundational pro case — blockers as “time to think,” relief of suffering, the open future preserved) → Ashley (the anti-gatekeeping radicalization — assessment-heavy models themselves harm; affirmation as default) → Gorin (the skeptic’s reply, Hastings Center Report 2024 — the diagnosis can’t bear the weight; evidence doesn’t support the affirmative default) → Priest (the state-vs-parents move — adolescents’ right to transition over parental objection, paired with mature-minor doctrine). Keystone: Feinberg’s open future claimed by both sides — blockers preserve options vs. the pathway forecloses them. One principle, opposite conclusions: the lecture’s spine in philosophical form, with a thinker students already know from genomics and enhancement.
  • The Cass Review (UK, 2024) and its remarkable aftermath: what it concluded and changed; the Yale critique and defenders’ replies; the BMA arc — members force a critical evaluation, the evaluation (May 2026) finds the methodology sound while faulting government implementation — as a trust-the-process exhibit.
  • The PATHWAYS trial pause (Feb 2026) as the equipoise lesson: “just run the trial” turns out to be ethically hard — consent, blinding, and community equipoise problems delayed it for years, then MHRA safety concerns paused it before recruitment. NHS England’s halt on new 16–17 hormone referrals (March 2026).
  • Preemptive balance: Sweden and Finland restricted pediatric care before Cass and outside Anglo-American politics.
  • The legal half, lean (constitutional toolkit is prior knowledge from the abortion-law lecture): U.S. v. Skrmetti (2025) — what the 6–3 holding actually was (age/medical-use classification, rational basis), and what it deliberately didn’t decide; the 27-state ban map vs. shield states (Minnesota is a refuge state — where most of our students will practice); EO 14187 and the post-ruling federal squeeze (CMS, OPM, hospitals dropping care preemptively, pressure moving toward adult care).
  • Parental authority, adolescent assent, mature-minor doctrine, and clinical gatekeeping — the paternalism lecture’s machinery applied.

Visual elements: - Figure (code-generated): care pathway by age and reversibility (typical, illustrative), with the contested decision points marked. - Table: the dueling authorities — AAP/Endocrine Society, Cass Review, HHS 2025 report, European agencies — what each concluded and what evidence standard each invoked. - Table: precaution argument vs. access argument — same evidence base, opposite defaults, what each risks being wrong about. - Sidebar: “What is ‘gender dysphoria’ in DSM-5-TR?” - Case box: a composite case (a 15-year-old patient, parents disagreeing) with a four-principles analysis. Composite only — no real minors. - Discussion prompt: “Where should the age line be for irreversible interventions, and who should decide?” - Discussion unit (dueling authorities): “Your patient’s parents bring you the HHS report; her physician cites the Endocrine Society. What does a trustworthy process look like here?” — callback to trusting process over authority.

1.10.2 L11b. Disability, Identity, and the Limits of Autonomy

Spine: the mere-difference vs. bad-difference dispute runs as the scoreboard through every case — models of disability, selective abortion, deaf embryo selection, body integrity dysphoria — each scored under both views, accumulating to a final grid.

  • Models of disability: medical model vs. social model vs. Shakespeare’s interactional view (the named “both” position completing the challenge→reply chain).
  • The disability paradox (Albrecht & Devlieger 1999) as the lecture’s empirical anchor: disabled people self-report quality of life far higher than outsiders — including clinicians — predict. For a nursing audience, the load-bearing fact: your quality-of-life predictions are systematically miscalibrated.
  • Barnes (“mere difference”) vs. Bognar and others (“bad difference”): is disability bad in itself or only because of how society is arranged? The disability paradox as Barnes’s evidence; Bognar’s reply.
  • The disability-rights critique of selective abortion (Asch) — paying off the NIPT setup from the genomics lecture: what the expressivist objection argues, and what it doesn’t.
  • The deaf-embryo-selection question as the hard case where the two spines cross.
  • Body integrity dysphoria (ICD-11 term; formerly BIID): when patients seek amputation of healthy limbs — what does respect for autonomy require? The Robert Smith case (Falkirk, late 1990s) as the real case box.
  • The analogy question, handled explicitly (3-slide discussion unit): critics of gender-affirming care argue BID and gender dysphoria are analogous; defenders publish disanalogies (evidence of benefit, nosology, outcomes). Where exactly does the analogy hold, and where does it break? Named argument-mapping, not insinuation.
  • One-line recap callbacks, not retellings: the MAID disability critique (Johnson vs. Singer); Feinberg’s open future.

Visual elements: - Figure (code-generated): medical vs. social vs. interactional models with one concrete example (wheelchair user + stairs vs. ramp). - Table: “Mere difference” vs. “bad difference” — what each accepts, rejects, and implies for selection and policy. - Scoreboard (recurring): each case scored under mere-difference and bad-difference readings, accumulating to a final grid. - Case box: the Robert Smith amputations — facts, the hospital’s response, the open question. - Discussion prompt: “If a deaf couple wants a deaf child via embryo selection, what should the clinic do?” - Discussion unit: the BID ↔︎ gender dysphoria analogy — map it, then break it (or defend it). - Image (public domain): the disability pride flag or relevant historical photograph (verify public domain status before use).

1.11 L12. Animal Ethics

1.11.1 L12a. Moral Status of Animals and the Ethics of Research

  • Three major views on animal moral status:
    • Kantian / indirect duties — animals matter only because of how their treatment affects humans.
    • Singer’s utilitarianism — equal consideration of equal interests; species is morally irrelevant.
    • Regan’s rights view — “subjects-of-a-life” have inherent value.
  • The 3 Rs of animal research (Russell & Burch, 1959): replacement, reduction, refinement.
  • IACUCs (the IRB-equivalent for animal research) — how they work.
  • Primate research: why it’s used (neuroscience, infectious disease), why it’s contested, current trends (declining NIH-funded chimp research).

Visual elements: - Figure (code-generated): spectrum diagram of moral-status views from Kantian to Regan, with where common positions land. - Table: Singer vs. Regan vs. Kantian view — what each says about eating meat, animal research, pets, wildlife. - Figure (code-generated): bar chart of US animal research use by species (NIH/USDA data). - Case box: The 2015 NIH decision to end chimpanzee research. - Sidebar: “What’s actually in an IACUC protocol?”

1.11.2 L12b. Industrial Animals, Xenotransplantation, and the Frontier

Spine: not all animal use is morally equal — scale, necessity, and benefit are what rank it. Students rank four uses up front, build the tools to evaluate the ranking, and discover the intuitive ordering (“high-tech = worse”) is often backwards. A running “ledger” motif accumulates the ranking; the climax shows the same logic that condemns the cheeseburger licenses the pig heart, while Regan’s rights view refuses to rank at all.

  • Industrial animal agriculture — the biggest use:
    • Scale and conditions (CAFOs); the welfare case from Part A, made concrete.
    • It harms humans too: antibiotic resistance (most U.S. antibiotics go to livestock) and zoonotic spillover (avian/swine flu, pandemic risk); environmental dimension in brief.
    • The reframe: anthropocentric public-health reasons and animal-welfare reasons converge — even a human-centered view condemns the antibiotic practice.
  • Does the research even work? — the validity debate:
    • The translation gap: most drugs that pass animal tests still fail in humans; weak predictive value undercuts the cost-benefit defense of research.
    • Policy turn: FDA Modernization Act 2.0 (2022) and the EU roadmap to phase out animal testing; NIH’s push toward non-animal methods.
    • The balanced reply: organs-on-chips can’t yet model a whole immune system or developing brain — phase-out is a destination, not a current capability.
  • Xenotransplantation — the high-tech, low-number use:
    • The organ shortage that drives it; how a pig is gene-edited (CRISPR antigen knockouts, PERV inactivation, human transgenes).
    • Cases since 2022: Bennett (heart), Faucette (heart), Slayman / Looney (kidneys), decedent studies.
    • Issues unique to xeno: welfare of designer pigs in isolation, xenozoonosis risk to a non-consenting public, consent under desperation.
  • The counterintuitive ranking (the climax): on the consequentialist math, a McDonald’s habit is worse than a pig-heart transplant — Singer, a critic of factory farming and much research, can consistently accept xenotransplantation. Regan’s rights view does not rank: using the pig as a means is wrong regardless of scale. The ranking is theory-dependent.
  • The frontier — uplifting (cognitive enhancement of animals):
    • Tie to the enhancement debate from genomics.
    • The paradox: raise an animal’s capacities and you raise its moral status — the “better” the research animal, the less we may use it.
    • Already real: human-neuron chimeras (human brain cells in animal brains) create beings of ambiguous status.
  • Connecting threads (cumulative payoff):
    • From abortion: Marquis’s “future like ours” — if a fetus’s future grounds a right to life, does a pig’s?
    • From genetics: engineering pigs for organs vs. creating a savior sibling — making a being to be used.
    • From end of life: is the pig’s death “killing for benefit,” and is it justified differently than risk to a human research subject — or than retrieving organs from the newly dead?

Visual elements: - Running motif: the “ledger” table ranking uses of animals by scale × harm × benefit, filled in across the deck. - Figure (code-generated): how a pig organ is gene-edited for human transplant (antigen knockouts, PERV inactivation, human transgenes — high level). - Figure (code-generated): drug-attrition funnel — compounds entering animal tests vs. surviving to human approval. - Table: major xenotransplantation cases since 2022 — recipient, organ, outcome, ethical issue raised. - Figure (code-generated): concept map of moral-status criteria from across the course applied to animals. - Case box: the David Bennett pig-heart transplant (2022) — patient, team, outcome, lessons. - Discussion prompt: “If you accept Marquis’s ‘future like ours’ argument against abortion, what does it say about killing a pig?”

1.12 Cross-chapter design notes

  • Image sourcing. All “public domain” labels should be verified before publication — Wikimedia Commons, NIH/NHGRI, CDC, US National Archives, and the Wellcome Collection (CC0 portion) are the safest sources. When uncertain, fall back to a code-generated figure.
  • Code-generated figures. All figures marked “code-generated” can be produced in matplotlib or with a TikZ Beamer-style approach if you want a consistent look across this and your LaTeX materials.
  • Case boxes and discussion prompts. Each subchapter has at least one of each. These are the high-leverage assessment points and also map well to your CSV quiz workflow.
  • Tying it together. L12b deliberately revisits L4, L6, L7, and L11 to make the course feel cumulative rather than modular — feel free to flag similar callbacks in L7b (→ L4), L11b (→ L5/L6), and L10b (→ L2).
# Case Paired Lecture
1 Dax Cowart — refusing burn treatment L2 Clinical relationship
2 Tuskegee Syphilis Study L3 Research ethics
3 Sylvain Lesné & the Aβ*56 affair — research misconduct and replication L3 Research ethics
4 Kate Cox — post-Dobbs medical exception L4 Abortion
5 Adriana Smith — brain death, pregnancy, and the limits of fetal-protection law L5 Reproductive ethics
6 He Jiankui CRISPR twins (2018) L6 Genomics & enhancement
7 Noelia Castillo — psychiatric suffering, capacity, and the limits of euthanasia law L7 End of life
8 Singapore’s health care system — cost, access, and what the US can (and can’t) learn L8 Justice
9 Andrew Wakefield & the MMR-autism myth — misinformation and public trust L9 Public health
10 Optum care-management algorithm L10 AI in medicine
11 U.S. v. Skrmetti — gender-affirming care, evidence, and the law L11 Gender, identity & disability
12 David Bennett — first pig-heart xenotransplant L12 Animal ethics